Codice Viola

Crowds gather to hear @EileenMOReilly @MSKCancerCenter talk on the immunological correlatives of @ElicioTx amphiphilic lymph node targeted vaccine directed against mutant KRAS in surgically resected #PancreaticCancer (and #ColorectalCancer) with ctDNA or CA19-9 positive minimal residual disease (AMPLIFY-201). The key data (albeit small numbers, limited follow up) is very similar to what was observed with mRNA vaccine in adjuvant setting - there is a subset of patients (around 50%) who generate potent T cell responses to the vaccine and these individuals do very well on the recurrence free survival scale. Then there is a subset (remaining 50%) that do not develop robust T cell responses and unfortunately those patients progress fairly rapidly. Now we need to figure - pre facto, not post - what differentiates the individuals who develop productive T cell responses from the ones who do not. #AACRPan23 @DrShubhamPant @MDAndersonNews

#AACRPan23 talk by Dr. Gulam Manji @columbiacancer on CheMoMETPANC 👉🏽 gemcitabine plus nab-paclitaxel + motixafortide (CXCR4 antagonist) + cemiplimib in advanced #PancreaticCancer. Responses observed in both primary & metastatic sites, with 64% partial responses & 27% stable disease. All patients in the trial received paired biopsies for deep correlative studies. Now moving to randomized phase 2.